BridgeBio Pharma, Inc. Selling, General and Administrative Expense
BridgeBio Pharma, Inc. (BBIO) reported Selling, General and Administrative Expense of $186.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-10
- BridgeBio Pharma, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $186.26M, a 44.22% increase year-over-year.
- BridgeBio Pharma, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $163.90M, a 54.09% increase year-over-year.
- BridgeBio Pharma, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $158.09M, a 66.79% increase year-over-year.
- BridgeBio Pharma, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $137.62M, a 99.98% increase year-over-year.
- BridgeBio Pharma, Inc. selling, general and administrative expense for fiscal 2025 was $531.23M, a 83.86% increase from fiscal 2024.
- BridgeBio Pharma, Inc. selling, general and administrative expense for fiscal 2024 was $288.93M, a 91.87% increase from fiscal 2023.
- BridgeBio Pharma, Inc. selling, general and administrative expense for fiscal 2023 was $150.59M, a 5.17% increase from fiscal 2022.
- BridgeBio Pharma, Inc. selling, general and administrative expense for fiscal 2022 was $143.19M, a 25.50% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $186.26M 10-Q · filed 2026-08-10 | $350.16M 10-Q · filed 2026-08-10 | $508.24M derived: sum of 3 quarters · filed 2026-08-10 | $645.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $163.90M 10-Q · filed 2026-05-07 | $321.98M derived: sum of 2 quarters · filed 2026-05-07 | $459.60M derived: sum of 3 quarters · filed 2026-05-07 | $588.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $158.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $295.71M derived: sum of 2 quarters · filed 2026-02-24 | $424.86M derived: sum of 3 quarters · filed 2026-08-10 | $531.23M 10-K · filed 2026-02-24 |
| 2025-09-30 | $137.62M 10-Q · filed 2025-10-29 | $266.77M derived: sum of 2 quarters · filed 2026-08-10 | $373.14M 10-Q · filed 2025-10-29 | $467.92M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $129.15M 10-Q · filed 2026-08-10 | $235.52M 10-Q · filed 2026-08-10 | $330.30M derived: sum of 3 quarters · filed 2026-08-10 | $399.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $106.36M 10-Q · filed 2026-05-07 | $201.15M derived: sum of 2 quarters · filed 2026-05-07 | $269.97M derived: sum of 3 quarters · filed 2026-05-07 | $329.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $94.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $163.60M derived: sum of 2 quarters · filed 2026-02-24 | $223.12M derived: sum of 3 quarters · filed 2026-02-24 | $288.93M 10-K · filed 2026-02-24 |
| 2024-09-30 | $68.82M 10-Q · filed 2025-10-29 | $128.34M derived: sum of 2 quarters · filed 2025-10-29 | $194.15M 10-Q · filed 2025-10-29 | $241.73M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $59.52M 10-Q · filed 2025-08-05 | $125.33M 10-Q · filed 2025-08-05 | $172.91M derived: sum of 3 quarters · filed 2026-02-24 | $208.69M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $65.81M 10-Q · filed 2025-04-29 | $113.39M derived: sum of 2 quarters · filed 2026-02-24 | $149.17M derived: sum of 3 quarters · filed 2026-02-24 | $185.29M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $47.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $83.36M derived: sum of 2 quarters · filed 2026-02-24 | $119.48M derived: sum of 3 quarters · filed 2026-02-24 | $150.59M 10-K · filed 2026-02-24 |
| 2023-09-30 | $35.78M 10-Q · filed 2024-11-12 | $71.90M derived: sum of 2 quarters · filed 2024-11-12 | $103.01M 10-Q · filed 2024-11-12 | $134.87M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $36.12M 10-Q · filed 2024-08-01 | $67.23M 10-Q · filed 2024-08-01 | $99.09M derived: sum of 3 quarters · filed 2025-02-20 | $130.28M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $31.11M 10-Q · filed 2024-05-02 | $62.97M derived: sum of 2 quarters · filed 2025-02-20 | $94.16M derived: sum of 3 quarters · filed 2025-02-20 | $130.58M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $31.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $63.05M derived: sum of 2 quarters · filed 2025-02-20 | $99.48M derived: sum of 3 quarters · filed 2025-02-20 | $143.19M 10-K · filed 2025-02-20 |
| 2022-09-30 | $31.19M 10-Q · filed 2023-11-02 | $67.61M derived: sum of 2 quarters · filed 2023-11-02 | $111.33M 10-Q · filed 2023-11-02 | $166.08M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $36.43M 10-Q · filed 2023-08-03 | $80.14M 10-Q · filed 2023-08-03 | $134.89M derived: sum of 3 quarters · filed 2024-02-22 | $180.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $43.71M 10-Q · filed 2023-05-04 | $98.46M derived: sum of 2 quarters · filed 2024-02-22 | $144.55M derived: sum of 3 quarters · filed 2024-02-22 | $190.52M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $54.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $100.83M derived: sum of 2 quarters · filed 2024-02-22 | $146.80M derived: sum of 3 quarters · filed 2024-02-22 | $192.21M 10-K · filed 2024-02-22 |
| 2021-09-30 | $46.08M 10-Q · filed 2022-11-03 | $92.05M derived: sum of 2 quarters · filed 2022-11-03 | $137.46M 10-Q · filed 2022-11-03 | $174.90M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $45.97M 10-Q · filed 2022-08-04 | $91.38M 10-Q · filed 2022-08-04 | $128.81M derived: sum of 3 quarters · filed 2023-02-23 | $164.83M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $45.41M 10-Q · filed 2022-05-05 | $82.84M derived: sum of 2 quarters · filed 2023-02-23 | $118.86M derived: sum of 3 quarters · filed 2023-02-23 | $156.83M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $37.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $73.45M derived: sum of 2 quarters · filed 2023-02-23 | $111.42M derived: sum of 3 quarters · filed 2023-02-23 | $145.68M 10-K · filed 2023-02-23 |
| 2020-09-30 | $36.02M 10-Q · filed 2021-11-04 | $73.98M derived: sum of 2 quarters · filed 2021-11-04 | $108.25M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $37.97M 10-Q · filed 2021-08-05 | $72.23M 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | $94.35M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |